Study summary

Methylone, a relative of MDMA, was put on a fast FDA track

Methylone status · Phase 3 program of two 300-person trials · FDA priority voucher April 24, 2026

What was tested

Methylone (TSND-201), a shorter-acting chemical relative of MDMA given in supervised sessions without a structured therapy program.

What they found

• The FDA granted a national priority voucher in April 2026, which shortens review once an application is filed.
• Phase 3 began after positive mid-stage results.
• No application has been filed yet.

What it means

The PTSD drug most likely to reach an FDA decision next.